ZG005 with chemo for advanced neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a new drug (ZG005) combined with two standard chemotherapy drugs (etoposide and cisplatin) for people with advanced neuroendocrine carcinoma that has spread or come back. The goal is to see if the combination works better than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your neuroendocrine cancer has spread or come back and cannot be cured with surgery.
- You are in good enough health to walk around and take care of yourself (ECOG score 0-1).
- Your cancer has not spread to your brain or spinal cord.
- You have not had any other cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This study tests whether a new drug called ZG006 works better than standard chemotherapy for advanced neuroendocrine carcinoma (a rare cancer that starts in hormone-producing cells). You'll be randomly assigned to receive either ZG006 or a chemotherapy your doctor chooses.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial tests a new drug combination (ZG005, Gecacitinib, and chemotherapy) for people with advanced solid tumors that cannot be removed by surgery. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug (LBL-024) combined with standard chemo as a first treatment for a rare and fast-growing neuroendocrine cancer (EP-NEC) that started outside the lungs. It may offer a new option for people whose cancer has spread and who haven't had treatment yet.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.